Primary and secondary prevention of stroke: A guideline;Guía de práctica clínica sobre prevención primaria y secundaria del ictus

Medicina Clinica

Volumn 133, Issue 19, 2009, Pages 754-762

  Rigau Comas, David ^a   Álvarez Sabin, José ^b   Gil Núñez, Antonio ^c   Abilleira Castells, Sonia ^d   Borras Pérez, Francesc Xavier ^e   Armario García, Pedro ^f   Arrieta Antón, Enrique ^g   Marañón Fernández, Eugenio ^c   Martí Canales, Juan Carlos ^h   Morales Ortiz, Ana ⁱ   Reverter Calatayud, Juan Carlos ^j   Sancristóbal Velasco, Esther ^k   Solà Arnau, Ivan ^a   Alonso Coello, Pablo ^l  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d Catalan Agency for Health Technology Assessment and Research   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL GENERAL DE CATALUNYA   (Spain)

^g Medicina Familiar Y Comunitaria   (Spain)

^h Centro de Salud San Antonio   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^j Dirección de Enfermeria   (Spain)

^k Servicio de Salud del Principado de Asturias   (Spain)

^l CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT;

ALCOHOL CONSUMPTION; ARTICLE; CAROTID ARTERY OBSTRUCTION; DIABETES MELLITUS; DIETARY INTAKE; DYSLIPIDEMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; OBESITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; RISK ASSESSMENT; SECONDARY PREVENTION; SITTING; STROKE;

HUMANS; LIFE STYLE; PRIMARY PREVENTION; RISK FACTORS; SECONDARY PREVENTION; STROKE;

EID: 70449527570     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2009.02.037     Document Type: Article

References (98)

1. o 2006/15.
2. Grupo de trabajo sobre GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. Madrid: Plan Nacional para el SNS del MSC. Instituto Aragonés de Ciencias de la Salud-I+CS; 2007.
3. The AGREE Collaboration. Appraisal of Guidelines for Research & Evaluation (AGREE) Instrument. [serial online] [citado 1 Jul 2008]. Disponible en: URL: http://www.agreecollaboration.org.
4. Arboix A, Díaz J, Pérez-Sempere A, Alvarez Sabin J, por el Comité ad hoc del Grupo de Estudio de Enfermedades Cerebrovasculares de la SEN. Ictus. Tipos etiológicos y criterios diagnósticos. En: Díez Tejedor E, editor. Guía para el diagnostico y tratamiento del ictus. Guías oficiales de la Sociedad Española de Neurología. Barcelona: Prous Science; 2006. p. 133-83.
5. Scottish Intercollegiate Guidelines Network: SIGN 50: A guideline developers' handbook. [serial online] [citado 1 de Jul 2008]. Disponible en: URL: http://www.sign.ac.uk.
6. Marrugat J., Arboix A., García-Eroles L., Salas T., Vila J., Castell C., et al. Estimación de la incidencia poblacional y la mortalidad de la enfermedad cerebrovascular establecida isquémica y hemorrágica en 2002. Rev Esp Cardiol 60 (2007) 573-580
7. Álvarez Sabin J., Alonso de Leciñana M., Gállego J., Gil-Peralta A., Casado I., Castillo J., et al. Plan de atención sanitaria al ictus. Neurología 21 (2006) 717-726
8. Comín E., Solanas P., Cabezas C., Subirana I., Ramos R., Gené-Badía J., et al. Rendimiento de la estimación del riesgo cardiovascular en España utilizando distintas funciones. Rev Esp Cardiol 60 (2007) 693-702
9. Anderson K.M., Wilson P.W.F., Odell P.M., and Kannel W.B. An updated coronary risk profile: A statement for health professionals. Circulation 83 (1991) 356-362
10. Marrugat J., Solanas P., D'Agostino R., Sullivan L., Ordovas J., Cordon F., et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol 56 (2003) 253-261
11. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 24 (2003) 987-1003
12. D'Agostino R.B., Vasan R.S., Pencina M.J., Wolf P.A., Cobain M., Massaro J.M., et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 117 (2008) 743-753
13. Marrugat J., Subirana I., Comin E., Cabezas C., Vila J., Elosua R., et al. Validity of an adaptation of the Framingham cardiovascular risk function: The VERIFICA study. J Epidemiol Community Health 61 (2007) 40-47
14. Sans S., Fitzgerald A.P., Royo D., Conroy R., and Graham I. Calibración de la tabla SCORE de riesgo cardiovascular para España. Rev Esp Cardiol 60 (2007) 476-485
15. Van Wijk I., Kappelle L.J., Van Gin J., Koudstaal P.J., Franke C.L., Vermeulen M., et al. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: A cohort study. Lancet 365 (2005) 2098-2104
16. Wolf P.A., D'Agostino R.B., O'Neal M.A., Sytkowski P., Kase C.S., Belanger A.J., et al. Secular trends in stroke incidence and mortality: The Framingham Study. Stroke 23 (1992) 1551-1555
17. Marrugat J., Sala J., and Aboal J. Epidemiology of cardiovascular disease in women. Rev Español Cardiol 59 (2006) 264-274
18. Sacco R.L., Boden-Albala B., Gan R., Chen X., Kargman D.E., Shea S., et al. Stroke incidence among white, black, and Hispanic residents of an urban community: The Northern Manhattan Stroke Study. Am J Epidemiol 147 (1998) 259-268
19. Howard G., Anderson R., Sorlie P., Andrews V., Backlund E., and Burke G.L. Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks: The National Longitudinal Mortality Study. Stroke 25 (1994) 2120-2125
20. Liao D., Myers R., Hunt S., Shahar E., Paton C., Burke G., et al. Familial history of stroke and stroke risk: The Family Heart Study. Stroke 28 (1997) 1908-1912
21. Reynolds K., Lewis B., Nolen J.D., Kinney G.L., Sathya B., and He J. Alcohol consumption and risk of stroke: A meta-analysis. JAMA 289 (2003) 579-588
22. Elkind M.S.V., Sciacca R., Boden-Albala B., Rundek T., Paik M.C., and Sacco R.L. Moderate alcohol consumption reduces risk of ischemic stroke - the Northern Manhattan Study. Stroke 37 (2006) 13-19
23. Emberson J.R., Shaper A.G., Wannamethee S.G., Morris R.W., and Whincup P.H. Alcohol intake in middle age and risk of cardiovascular disease and mortality: Accounting for intake variation over time. Ame J Epidemiol 169 (2005) 856-863
24. Kaner EFS, Beyer F, Dickinson HO, Pienaar E, Campbell F, Schlesinger C, et al. Efectividad de las intervenciones breves para controlar el consumo de alcohol en poblaciones que asisten a centros de atención primaria. En: La Biblioteca Cochrane Plus. Número 4. Oxford: Update Software Ltd; 2007. [serial online] [citado 1 Jul 2008]. Disponible en: URL: http://www.update-software.com.
25. Shinton R., and Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 298 (1989) 789-794
26. Heuschmann P.U., Heidrich J., Wellmann J., Kraywinkel K., and Keil U. Stroke mortality and morbidity attributable to passive smoking in Germany. Eur J Cardiovasc Prev Rehabil 14 (2007) 793-795
27. Wannamethee S.G., Shaper A.G., and Walker M. Changes in physical activity, mortality, and incidence of coronary heart disease in older men. Lancet 351 (1998) 1603-1608
28. Lancaster T, Stead LF. Asesoramiento médico para el abandono del hábito de fumar. En: La Biblioteca Cochrane Plus. Número 4. Oxford: Update Software Ltd; 2007. [serial online] [citado 1 Jul 2008]. Disponible en: URL: http://www.update-software.com.
29. o: CD000146. doi:10.1002/14651858.CD000146.pub3.
30. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007;CD000031. doi:10.1002/14651858.CDOOOO31.pub3.
31. o: CD006103. doi:10.1002/14651858.CD006103.pub3.
32. Hooper L, Summerbell CD, Higgins JPT, Thompson RL, Clements G, Capps N, et al. Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database Syst Rev 2000;CD002137. doi:10.1002/14651858.CD002137.
33. He K., Song Y., Daviglus M.L., Liu K., Van Horn L., Dyer A.R., et al. Fish consumption and incidence of stroke: A meta-analysis of cohort studies. Stroke 35 (2004) 1538-1542
34. Feng F.J., Nowson C.A., and MacGregor G.A. Fruit and vegetable consumption and stroke. Lancet 367 (2006) 320-326
35. He F.J., and MacGregor G.A. Effect of modest salt reduction on blood pressure: A meta-analysis of randomized trials. Implications for public health. J Hum Hypertens 16 (2002) 761-770
36. Brotons C., Royo-Bordonada M.A., Álvarez-Sala L., Armario P., Artigao R., Conthe P., et al. Adaptación española de la Guía Europea de Prevención Cardiovascular. Rev Esp Salud Pública 78 (2004) 435-438
37. Wendel-Vos G.C., Schuit A.J., Feskens E.J., Boshuizen H.C., Verschuren W.M., Saris W.H., et al. Physical activity and stroke. A meta-analysis of observational data. Int J Epidemiol 33 (2004) 787-798
38. Lawes C.M.M., Bennett D.A., Feigin V.L., and Rodgers A. Blood pressure and stroke: An overview of published reviews. Stroke 35 (2004) 776-785
39. Dickinson H.O., Manson J.M., Nicolson D.J., Campbell F., Beyer F.R., Cook S.W., et al. Lifestyle interventions to reduce raised blood pressure: A systematic review of randomised controlled trials. J Hypertens 24 (2006) 215-233
40. Turnbull F. Blood pressure lowering treatment trialists' collaboration effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Med 165 (2005) 1410-1419
41. Psaty B.M., Lumley T., Furberg C.D., Schellenbaum G., Pahor M., Alderman M.H., et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis. JAMA 289 (2003) 2534-2544
42. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007;CD002003. doi:10.1002/14651858.CD002003.pub2.
43. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 (1998) 1755-1762
44. Mancia G., DeBacker G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. 2007 Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Eur Heart J 28 (2007) 1462-1536
45. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 370 (2007) 829-840
46. Rashid P., Leonardi-Bee J., and Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: A systematic review. Stroke 34 (2003) 2741-2748
47. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 (2001) 1033-1041
48. Chapman N., Huxley R., Anderson C., Bousser M.G., Chalmers J., Colman S., et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: The PROGRESS trial. Stroke 35 (2004) 116-121
49. Schrader J., Luders S., Kulschewski A., Hammersen F., Plate K., Berger J., et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 36 (2005) 1218-1226
50. Vivancos Mora J., and Gil-Núñez A.C. Lipids and stroke: The opportunity of lipid-lowering treatment. Cerebrovasc Dis 20 (2005) 53-67
51. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al., Cholesterol Treatment Trialists' (CTT) collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
52. O'Regan C., Wu P., Arora P., Perri D., and Mills E.J. Statin therapy in stroke prevention: A meta-analysis involving 121,000 patients. Am J Med 121 (2008) 24-33
53. Nakamura H., Arakawa K., Itakura H., Kitabatake A., Goto Y., Toyota T., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 368 (2006) 1155-1163
54. Amarenco P., Labreuche J., Lavallee P., and Touboul P.J. Statins in stroke prevention and carotid atherosclerosis: Systematic review and up-to-date meta-analysis. Stroke 35 (2004) 2902-2909
55. Kearney P.M., Blackwell L., Collins R., Keech A., Simes J., Peto R., et al. Cholesterol Treatment Trialists' (CTT) collaborators efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 371 (2008) 117-125
56. o 12. February 2007. [serial online] [citado 1 Jul 2008]. Disponible en: URL: http://www.bcbs.com/betterknowledge/tec/vols/21/21_12.pdf.
57. Amarenco P., Bogousslavsky J., Callahan A., Goldstein L.B., Hennerici H., Rudolf A.E., et al. High-dose atorvastatin after stroke or transient ischemic attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) investigators. N Engl J Med 355 (2006) 549-559
58. Vergouwen M., Haan R.J., Vermeulen M., and Roos Y. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 39 (2008) 497-502
59. Hayward R.A., Hofer T.P., and Vijan S. Narrative review: Lack of evidence for recommended low-density lipoprotein treatment targets: A solvable problem. Ann Intern Med 145 (2006) 520-530
60. Folsom A.R., Rasmussen M.L., Chambless M.E., Howard G., Cooper L.S., Schmidt M.I., et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) study investigators. Diabetes Care 22 (1999) 1077-1083
61. o 128. (Prepared by the McMaster University Evidence-based Practice Center under Contract No. 290-02-0020). AHRQ Pub. No 05-E026-2. Rockville, MD: Agency for Healthcare Research and Quality. September 2005 [citado 15/4/2009]. Disponible en: http://www.ahrq.gov/clinic/epcsums/impglusum.pdf.
62. Grupo de trabajo de la Guía de Práctica Clínica sobre Diabetres tipo 2. Guía de Práctica Clínica sobre Diabetes tipo 2. Madrid: Plan Nacional para el SNS del MSC. Agencia de Evaluación de Tecnologías Sanitarias del País Vasco; 2008.
63. Grupo de trabajo semFYC y GEECV-SEN. Manejo coordinado y prevención del ictus. Consenso de la Sociedad Española de Medicina Familiar y Comunitaria (semFYC) y del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología (GEECV-SEN). Neurología 3 (2007) 1-40
64. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
65. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
66. Jood K., Jern C., Wilhelmsen L., and Rosengren A. Body mass index in mid-life is associated with a first stroke in men: A prospective population study over 28 years. Stroke 35 (2004) 2764-2769
67. Njølstad I., Arnesen E., and Lund-Larsen P.G. Body height, cardiovascular risk factors, and risk of stroke in middle-aged men and women: A 14-year follow-up of the Finmark Study. Circulation 94 (1996) 2877-2882
68. Suk S.H., Sacco R.L., Boden-Albala B., Cheun J.F., Pittman J.G., Elkind M.S., et al. For the Northern Manhattan Stroke Study. Abdominal obesity and risk of ischemic stroke: The Northern Manhattan Stroke Study. Stroke 34 (2003) 1586-1592
69. Mulrow CD, Chiquette E, Angel L, Cornell J, Summerbell C, Anagnostelis B. Dieting to reduce body weight for controlling hypertension in adults. Cochrane Database Syst Rev 2008;CD000484. doi:10.1002/14651858.CD000484.pub2.
70. o 4. Oxford: Update Software Ltd.; 2007 [serial online] [citado 1 Jul 2008]. Disponible en: URL: http://www.update-software.com.
71. McTigue, Harris R., Hemphill B., Lux L., Sutton S., Bunton A., et al. Screening and interventions for obesity in adults: Summary of the evidence for the U.S. preventive task force. Ann Intern Med 139 (2003) 933-949
72. Maggard M.A., Shugarman L.R., Suttorop M., Maglione M., Sugerman H.J., Livingstone E.H., et al. Meta-analysis: Surgical treatment of obesity. Ann Intern Med 142 (2005) 547-559
73. Aguilar M, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005;CD001927. doi:10.1002/14651858.CD001927.pub2.
74. Aguilar M, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2007;CD006186. doi:10.1002/14651858.CD006186.pub2.
75. Saxena R, Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev 2004;CD000185. doi:10.1002/14651858.CD000185.pub2.
76. Saxena R, Koudstaal PJ. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev 2004;CD000187. doi:10.1002/14651858.CD000187.pub2.
77. Hart R.G., Pearce L.A., and Aguilar M.I. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007) 857-867
78. Gage B.F., Yan Y., Milligan P.E., Waterman A.D., Culverhouse R., Rich M.W., et al. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 151 (2006) 713-719
79. Álvarez García B., Escribano Ferrer J.M., and Matas Docampo M. Isquemia cerebrovascular extracraneal, bases generales y diagnóstico. Tratado de las Enfermedades Vasculares vol. II (2006), Viguera, Barcelona 711-728
80. O'Leary D.H., Polak J.F., Kronmal R.A., Kittner S.J., Bond M.G., Wolfson Jr. S.K., et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke 23 (1992) 1752-1760
81. Chambers BR, Donnan GA. Carotid endarterectomy for asymptomatic carotid stenosis. Cochrane Database Syst Rev 2005;CD001923. doi:10.1002/14651858.CD001923.pub2.
82. Luebke T., Aleksic M., and Brunkwall J. Meta-analysis of randomized trials comparing carotid endarterectomy and endovascular treatment. Eur J Vasc Endovasc Surg 34 (2007) 470-479
83. Cina CS, Clase CM, Haynes RB. Carotid endarterectomy for symptomatic carotid stenosis. Cochrane Database Syst Rev 1999;CD001081. doi:10.1002/14651858.CD001081.pub2.
84. Rothwell P.M., Eliasziw M., Gutnikov S.A., Warlow C.P., Barnett H.J.M., and for the Carotid Endarterectomy Triallist Collaboration. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 365 (2004) 915-924
85. Mayberg M.R., Wilson S.E., Yatsu F., Weiss D.G., Messina L., Hershey L.A., et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis: Veterans Affairs Cooperative Studies Program 309 Trialist Group. JAMA 266 (1991) 3289-3294
86. Bartolucci A.A., and Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 98 (2006) 746-750
87. Berger J.S., Roncaglioni M.C., Avanzini F., Pangrazzi I., Tognoni G., and Brown D.L. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA 295 (2006) 306-313
88. Hayden M., Pignone M., Phillips C., and Mulrow C. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 136 (2002) 161-172
89. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
90. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in people at risk of ischemic events (CAPRIE). Lancet 348 (1996) 1329-1339
91. Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F. Triusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev 2005;CD004296. doi:10.1002/14651858.CD004296.pub2.
92. Verro P., Gorelick P.B., and Nguyen D. Aspirin plus dipiridamole versus aspirin for prevention of vascular events after stroke or TIA. Stroke 39 (2008) 1358-1363
93. Sacco R.L., Diener H.C., Yusuf S., Cotton D., Ounupuu S., Lawton W., et al. Aspirin and extended-release dypiridamole versus clopidogrel for recurrent stroke. N Engl J Med 359 (2008) 1238-1251
94. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Boden W.E., Cacoub P., et al., CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
95. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
96. Algra A, De Schryver EL, Van Gijn J, Kappelle LJ, Koudstaal PJ. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2006;CD001342. doi:10.1002/14651858.CD001342.pub2.
97. Sanmuganathan P.S., Ghahramani P., Jackson P.R., Wallis E.J., and Ramsay L.E. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85 (2001) 265-271
98. Stroke - prevention is better than cure [Editorial]. Lancet 369 (2007) 247